Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

door Freiburghaus, Catja, Emruli, Venera Kuci, Johansson, Angelica, Eskelund, Christian Winther, Grønbæk, Kirsten, Olsson, Roger, Ek, Fredrik, Jerkeman, Mats, Ek, Sara
Gepubliceerd in BMC Cancer (2018)

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

door Eskelund, Christian Winther, Albertsson-Lindblad, Alexandra, Kolstad, Arne, Laurell, Anna, Räty, Riikka, Pedersen, Lone Bredo, Geisler, Christian Hartmann, Jerkeman, Mats, Grønbæk, Kirsten
Gepubliceerd in Haematologica (2018)

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

door Eskelund, Christian Winther, Dimopoulos, Kostas, Kolstad, Arne, Glimelius, Ingrid, Räty, Riikka, Gjerdrum, Lise Mette Rahbek, Sonnevi, Kristina, Josefsson, Pär, Nilsson-Ehle, Herman, Bentzen, Hans H. N., Fagerli, Unn Merete, Kuittinen, Outi, Haaber, Jacob, Niemann, Carsten Utoft, Pedersen, Lone Bredo, Larsen, Maria Torp, Geisler, Christian Hartmann, Hutchings, Martin, Jerkeman, Mats, Grønbæk, Kirsten
Gepubliceerd in Hemasphere (2020)